FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Novartis AG Common Stock
(NY:
NVS
)
141.00
UNCHANGED
Delayed Quote
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
59
60
Next >
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
↗
May 08, 2024
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.
Via
Benzinga
Topics
Artificial Intelligence
Axmed raises $2 million to transform access to critical medicines in low and middle income countries
May 08, 2024
Axmed’s B2B marketplace aggregates demand for critical medicines in underserved regions to improve the availability, affordability, and distribution of life-saving medicine.
Via
News Direct
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Is NYSE:NVS a Good Fit for Dividend Investing?
↗
May 07, 2024
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?
Via
Chartmill
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
↗
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
↗
April 23, 2024
Shares have risen markedly over the past two days and gained again Tuesday.
Via
Investor's Business Daily
2 Magnificent Dividend Stocks to Hold for the Next Decade
↗
May 05, 2024
The dividend is just one reason to buy these stocks.
Via
The Motley Fool
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
↗
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
↗
April 29, 2024
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...
Via
Benzinga
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
↗
April 29, 2024
The company is projected to bring in increasing sales through at least 2029.
Via
Investor's Business Daily
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
↗
April 28, 2024
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...
Via
Talk Markets
What's Going On With Pfizer Stock On Thursday?
↗
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
↗
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Why Novartis Stock Topped the Market on Tuesday
↗
April 23, 2024
A double beat on the latest quarterly results and raised guidance made investors happy.
Via
The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
↗
April 23, 2024
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by...
Via
Benzinga
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
↗
April 23, 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
↗
April 23, 2024
Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. Spotify shares jump 17% on earnings.
Via
Benzinga
Topics
Economy
Stocks
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
↗
April 23, 2024
NVS earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
↗
April 23, 2024
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
Via
Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
↗
April 23, 2024
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose...
Via
Benzinga
Topics
Bonds
Top Analyst Reports For Novartis, American Express & ConocoPhillips
↗
April 22, 2024
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
Via
Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
↗
April 19, 2024
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."
Via
Investor's Business Daily
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
↗
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
↗
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
↗
April 17, 2024
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.
Via
Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
↗
April 17, 2024
These income stocks look like good options at current levels.
Via
The Motley Fool
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
↗
April 16, 2024
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via
Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
↗
April 14, 2024
Think globally with this high-yielding ETF.
Via
The Motley Fool
Topics
ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
↗
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
59
60
Next >
